Ruth Ann Marrie1, Bo Nancy Yu2, Stella Leung2, Lawrence Elliott2, Sharon Warren3, Christina Wolfson4, Helen Tremlett5, James Blanchard2, John D Fisk6. 1. Department of Internal Medicine, University of Manitoba, Winnipeg, Canada; Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada. Electronic address: rmarrie@hsc.mb.ca. 2. Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada. 3. Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Canada. 4. Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada; Research Institute of the McGill University Health Centre, Montreal, Canada. 5. Department of Medicine (Neurology), University of British Columbia, Vancouver, Canada. 6. Departments of Psychiatry and Medicine, Dalhousie University, Halifax, Canada.
Abstract
OBJECTIVE: Fibromyalgia adversely affects quality of life, yet little is known of the epidemiology of this condition in MS. We aimed to validate and apply administrative case definitions for fibromyalgia in MS. METHODS: Using administrative health data we identified persons with MS and an age-, sex- and geographically-matched general population (GP) cohort. Case definitions for fibromyalgia were developed using ICD-9/10 codes, validated against medical records, and applied to evaluate the incidence and prevalence of fibromyalgia. RESULTS: The case definition for fibromyalgia with ≥5 hospital or physician claims in 3 years had a sensitivity of 60%, specificity of 98%, and agreed moderately with medical records (κ=0.48). In 2005, the age-standardized prevalence of fibromyalgia was 6.82% (95% CI: 5.91-7.72) in the MS population and 3.04% (95% CI: 2.77-3.32) in the GP. After adjustment for age, sex and year, the incidence of fibromyalgia was 44% higher in the MS than the GP (IRR 1.44; 95% CI: 1.01-2.07). The incidence of fibromyalgia increased slightly over time in both populations. CONCLUSION: The incidence and prevalence of fibromyalgia are higher in the MS population than the general population. Fibromyalgia should be considered in the management of pain in persons with MS.
OBJECTIVE:Fibromyalgia adversely affects quality of life, yet little is known of the epidemiology of this condition in MS. We aimed to validate and apply administrative case definitions for fibromyalgia in MS. METHODS: Using administrative health data we identified persons with MS and an age-, sex- and geographically-matched general population (GP) cohort. Case definitions for fibromyalgia were developed using ICD-9/10 codes, validated against medical records, and applied to evaluate the incidence and prevalence of fibromyalgia. RESULTS: The case definition for fibromyalgia with ≥5 hospital or physician claims in 3 years had a sensitivity of 60%, specificity of 98%, and agreed moderately with medical records (κ=0.48). In 2005, the age-standardized prevalence of fibromyalgia was 6.82% (95% CI: 5.91-7.72) in the MS population and 3.04% (95% CI: 2.77-3.32) in the GP. After adjustment for age, sex and year, the incidence of fibromyalgia was 44% higher in the MS than the GP (IRR 1.44; 95% CI: 1.01-2.07). The incidence of fibromyalgia increased slightly over time in both populations. CONCLUSION: The incidence and prevalence of fibromyalgia are higher in the MS population than the general population. Fibromyalgia should be considered in the management of pain in persons with MS.
Authors: Ruth Ann Marrie; Nadia Reider; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Gary R Cutter; Stephen C Reingold; Jeffrey Cohen Journal: Mult Scler Date: 2014-12-23 Impact factor: 6.312
Authors: Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Stella Leung; Nancy Yu Journal: Neurology Date: 2015-05-27 Impact factor: 9.910
Authors: Ruth Ann Marrie; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sørensen; Stephen Reingold; Gary Cutter; Nadia Reider Journal: Mult Scler Date: 2015-01-26 Impact factor: 6.312